Mounjaro and Gout: Does Tirzepatide Affect Uric Acid Levels?

Gout is one of the most common inflammatory joint conditions in the UK, and patients considering Mounjaro often ask whether tirzepatide is safe when uric acid levels are already elevated. It is a reasonable concern. Rapid weight loss has long been associated with transient rises in serum uric acid, and for anyone with a history of gout, that possibility can feel like a serious barrier to starting treatment. The good news is that the clinical picture is more encouraging than many patients expect, and with the right medical supervision, Mounjaro can be used safely alongside a gout management plan.

Yes, in most cases you can take Mounjaro (tirzepatide) if you have gout or elevated uric acid levels, but your prescribing doctor needs to know your full history. Tirzepatide itself does not cause gout, and emerging evidence suggests that GLP-1 receptor agonists may actually help reduce serum uric acid over time. The main risk is during the early weeks of rapid weight loss, when uric acid can temporarily spike as fat tissue breaks down. At CutKilo, our doctors review your uric acid history, current medications and flare frequency before prescribing, and we use extended titration schedules to reduce any early metabolic stress on your joints.

If you are already taking allopurinol, febuxostat or colchicine, those medications can and should continue alongside Mounjaro. The combination is safe and provides an extra layer of protection during the weight loss phase.

Uric acid is a waste product created when the body breaks down purines, compounds found naturally in certain foods and in your own cells. Normally the kidneys filter uric acid out through urine. When levels build up in the blood, crystals can form in the joints, triggering the intense pain and swelling of a gout flare.

Body weight plays a direct role in this process. Adipose tissue is metabolically active and contributes to higher baseline uric acid production. Visceral fat in particular drives low-grade inflammation that impairs the kidneys’ ability to excrete uric acid efficiently. Research published in the Annals of the Rheumatic Diseases has shown that for every 5 kg of weight lost, serum uric acid falls by approximately 0.3 mg/dL on average, and the frequency of gout flares decreases significantly over the following 12 months.

This means that sustainable weight loss is one of the most effective long-term strategies for managing gout, even though the early stages of rapid weight loss can temporarily push uric acid in the wrong direction.

Tirzepatide is a dual GIP/GLP-1 receptor agonist. Beyond its effects on appetite and blood sugar, it influences several metabolic pathways that are relevant to uric acid metabolism.

Data from the SURMOUNT clinical trial programme showed that participants taking tirzepatide experienced a measurable reduction in serum uric acid over the 72-week treatment period. This reduction was observed consistently across the 5 mg, 10 mg and 15 mg dose groups. The mechanism appears to involve improved renal uric acid clearance, reduced insulin resistance (which itself impairs uric acid excretion) and a decrease in the chronic inflammatory state driven by excess adipose tissue.

A secondary analysis published in Diabetes, Obesity and Metabolism found that tirzepatide reduced serum uric acid by an average of 0.6 mg/dL compared to placebo over 40 weeks. While this is a modest reduction, it moves in the protective direction and suggests that Mounjaro does not worsen the underlying metabolic conditions that drive gout.

The first 8 to 12 weeks of any significant weight loss programme carry the highest risk for a gout flare. This is not unique to Mounjaro and applies equally to caloric restriction, bariatric surgery and other GLP-1 medications (and can be compounded by alcohol consumption). The reason is straightforward: as fat cells shrink, they release stored purines and other metabolic byproducts into the bloodstream. The kidneys cannot always clear this surge quickly enough, and serum uric acid rises before it eventually falls.

For patients with a history of gout, this temporary spike can trigger a flare even if uric acid levels have been well controlled for months. The risk is highest in patients who lose weight very rapidly, which is why CutKilo uses a gradual titration approach. Starting at the lowest effective dose and increasing slowly gives the body time to adjust its purine metabolism without overwhelming the kidneys.

Staying well hydrated during this period is also essential. Adequate water intake supports renal uric acid clearance and reduces crystal formation. We recommend a minimum of 2 litres of water daily, with more during warmer months or if you are physically active.

One of the most common questions we hear at CutKilo is whether existing gout medications should be stopped before starting Mounjaro. The answer is almost always no. Urate-lowering therapies such as allopurinol and febuxostat should be continued throughout treatment. These medications work by different mechanisms to tirzepatide and there are no known drug interactions between them.

If you are taking colchicine for flare prevention, this can also continue safely. Some patients on prophylactic colchicine find that their need for it decreases over time as weight loss improves their baseline uric acid levels, but any dose reduction should be guided by your rheumatologist or GP rather than made independently.

Non-steroidal anti-inflammatory drugs (NSAIDs) such as naproxen and indomethacin remain appropriate for managing acute flares during Mounjaro treatment. Patients should be aware that tirzepatide can slow gastric emptying, which may affect how quickly oral medications are absorbed. Taking NSAIDs with food and allowing extra time for onset of action is a practical step during the early titration phase.

You should contact your prescribing doctor or CutKilo clinical team if you experience a gout flare during Mounjaro treatment, particularly if it is your first flare in over 12 months or if it affects a joint that has not been involved before. A single flare does not mean you need to stop treatment, but your doctor may recommend a temporary pause in dose escalation, a short course of anti-inflammatory medication, or a review of your urate-lowering therapy dose.

If you have tophi (visible uric acid deposits under the skin) or a history of uric acid kidney stones, these are not absolute contraindications to Mounjaro, but they do require closer monitoring. Your doctor may request blood tests to check serum uric acid levels at baseline and at regular intervals during treatment, typically every 8 to 12 weeks in the first six months.

Mounjaro is not contraindicated in patients with gout, and the evidence suggests that tirzepatide may actually help reduce serum uric acid over time. The main risk is a temporary increase in flare likelihood during the first few months of rapid weight loss, which can be managed with continued urate-lowering therapy, adequate hydration and a gradual dose titration schedule. If you have gout and are considering Mounjaro, the most important step is to ensure your prescribing doctor has your full history so they can tailor your treatment plan accordingly.

Does Mounjaro cause gout?

No. Tirzepatide does not cause gout. However, rapid weight loss during the early weeks of treatment can temporarily raise uric acid levels, which may trigger a flare in patients who are already predisposed. This is a weight loss effect, not a drug effect, and it resolves as your body adjusts.

Should I stop allopurinol before starting Mounjaro?

No. Continue your allopurinol or other urate-lowering therapy throughout Mounjaro treatment. There are no drug interactions, and maintaining your urate-lowering medication provides important protection during the early weight loss phase.

Can Mounjaro lower uric acid levels?

Clinical trial data from the SURMOUNT programme suggests that tirzepatide reduces serum uric acid modestly over time. This is likely due to improved insulin sensitivity, reduced inflammation and enhanced renal uric acid clearance associated with weight loss and the drug’s metabolic effects.

What should I do if I get a gout flare on Mounjaro?

Treat the flare with your usual medication (NSAIDs, colchicine or corticosteroids as directed by your doctor). Contact your prescribing team to discuss whether a temporary pause in dose escalation is appropriate. A single flare does not mean you need to stop Mounjaro.

How much water should I drink on Mounjaro if I have gout?

Aim for at least 2 litres of water daily. Adequate hydration supports renal uric acid clearance and reduces the risk of crystal formation. Increase your intake during exercise or warm weather.